AbbVie Ends Rova-T Program as 3rd Lung Cancer Study Fails - Nasdaq

AbbVie Ends Rova-T Program as 3rd Lung Cancer Study Fails  Nasdaq

AbbVie, Inc.ABBV announced that it is discontinuing development of its small-cell lung cancer (SCLC) candidate rovalpituzumab tesirine or Rova-T after failure ...



Comments

Popular posts from this blog

Oncology: The disease, dynamics & challenges of market research

A Review of the Etiology and Epidemiology of Bladder Cancer: All ...

Lung Cancer Among People Who Never Smoked